Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07245316

Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
340 (estimated)
Sponsor
Jeong Eon Lee · Academic / Other
Sex
Female
Age
35 Years
Healthy volunteers
Not accepted

Summary

This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy.

Conditions

Interventions

TypeNameDescription
PROCEDUREAvoiding surgeryAvoiding surgery in hormone-receptor positive atypical ductal hyperplasia and in-situ carcinoma treated with endocrine treatment

Timeline

Start date
2025-12-01
Primary completion
2032-12-31
Completion
2032-12-31
First posted
2025-11-24
Last updated
2025-11-24

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT07245316. Inclusion in this directory is not an endorsement.

Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine (NCT07245316) · Clinical Trials Directory